ScholarIQanswers from OpenAlex & ORCID
Philip D. Leming
ResearcherPublications, citations & collaboration network
Philip D. Leming is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Philip D. Leming have?
ScholarIQindexed works
Philip D. Leming has 44 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Philip D. Leming have?
ScholarIQcitation count
Philip D. Leming has 19,291 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Philip D. Leming?
ScholarIQh-index
Philip D. Leming has an h-index of 22 in OpenAlex.
What is the i10-index of Philip D. Leming?
ScholarIQi10-index
Philip D. Leming has an i10-index of 23 in OpenAlex.
What is the ORCID of Philip D. Leming?
ScholarIQorcid
The ORCID for Philip D. Leming is on the source record.
What is the OpenAlex record for Philip D. Leming?
ScholarIQopenalex
The OpenAlex for Philip D. Leming is on the source record.
What are the most-cited papers on Philip D. Leming?
ScholarIQmost cited works
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Scott Gettinger, Leora Horn, Leena Gandhi, David R. Spigel, Scott Antonia, Naiyer A. Rizvi, John D. Powderly, Rebecca S. Heist, Richard D. Carvajal, David M. Jackman, Lecia V. Sequist, David C. Smith, Philip D. Leming, David P. Carbone, Mary Pinder-Schenck, Suzanne L. Topalian, F. Stephen Hodi, Jeffrey A. Sosman, Mario Sznol, David F. McDermott, Drew M. Pardoll, Vindira Sankar, Christoph M. Ahlers, Mark Salvati, Jon M. Wigginton, Matthew D. Hellmann, Georgia Kollia, Ashok Gupta, Julie R. Brahmer
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
Scott Gettinger, Leora Horn, David M. Jackman, David R. Spigel, Scott Antonia, Matthew D. Hellmann, John D. Powderly, Rebecca S. Heist, Lecia V. Sequist, David C. Smith, Philip D. Leming, William J. Geese, Dennis J. Yoon, Ang Li, Julie R. Brahmer